{"id":"https://openalex.org/W2463257517","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.9055","title":"Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).","display_name":"Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2463257517","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.9055","mag":"2463257517"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.9055","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.9055","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.9055","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047177507","display_name":"Jeffrey S. Weber","orcid":"https://orcid.org/0000-0002-4962-2957","observed_orcids":["https://orcid.org/0000-0002-4962-2957"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey S. Weber","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026672076","display_name":"Geoffrey Thomas Gibney","orcid":"https://orcid.org/0000-0002-5401-8498","observed_orcids":["https://orcid.org/0000-0002-5401-8498"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey Thomas Gibney","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100605698","display_name":"Bin Yu","orcid":"https://orcid.org/0000-0002-8827-1256","observed_orcids":["https://orcid.org/0000-0002-8827-1256"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bin Yu","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052521597","display_name":"Pingyan Cheng","orcid":"https://orcid.org/0009-0003-0205-1418","observed_orcids":["https://orcid.org/0009-0003-0205-1418"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"PingYan Cheng","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068571006","display_name":"Alberto J. Martinez","orcid":"https://orcid.org/0000-0002-9061-8650","observed_orcids":["https://orcid.org/0000-0002-9061-8650"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alberto J Martinez","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014273171","display_name":"Jodi L. Kroeger","orcid":"https://orcid.org/0000-0001-7783-3439","observed_orcids":["https://orcid.org/0000-0001-7783-3439"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jodi Kroeger","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014072944","display_name":"Jillene Freed","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jillene Freed","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063611038","display_name":"Allison D. Richards","orcid":"https://orcid.org/0000-0003-3438-5589","observed_orcids":["https://orcid.org/0000-0003-3438-5589"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allison Richards","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102319325","display_name":"Xiuhua Zhao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiuhua Zhao","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055925608","display_name":"Michael J. Schell","orcid":"https://orcid.org/0000-0003-4594-6601","observed_orcids":["https://orcid.org/0000-0003-4594-6601"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Schell","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I3019308854"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"9055","last_page":"9055"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9440000057220459},{"id":"https://openalex.org/keywords/unresectable-melanoma","display_name":"unresectable melanoma","score":0.8149999976158142},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7620000243186951},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.8709999918937683},{"id":"https://openalex.org/keywords/hla-dr","display_name":"HLA-DR","score":0.8109999895095825},{"id":"https://openalex.org/keywords/t-cell-subsets","display_name":"T cell subsets","score":0.7120000123977661},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.5809999704360962},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.546999990940094},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6819999814033508},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8939999938011169},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.5479999780654907},{"id":"https://openalex.org/keywords/multipeptide-vaccine","display_name":"multipeptide vaccine","score":0.6679999828338623},{"id":"https://openalex.org/keywords/hla-a-0201","display_name":"HLA-A*0201","score":0.7210000157356262}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.9522132873535156},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9469169974327087},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9141416549682617},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6348754167556763},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5974628925323486},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5826876759529114},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5755158066749573},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2864637076854706},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.20718401670455933},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.9055","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.9055","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.9055","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2243558653","https://openalex.org/W2267367070","https://openalex.org/W2762827891","https://openalex.org/W2560468940","https://openalex.org/W2135707184","https://openalex.org/W2313175236","https://openalex.org/W2587867179","https://openalex.org/W2602205881","https://openalex.org/W2739577140","https://openalex.org/W2891745547"],"abstract_inverted_index":{"9055":[0],"Background:":[1],"PD-1":[2,305],"antibodynivolumab":[3],"was":[4,131,140,169,176,185,302,325],"administered":[5],"with/without":[6],"a":[7,243],"multi-peptide":[8],"vaccine":[9],"to":[10,49,75,220,356],"126":[11],"patients":[12],"(pts)":[13],"with":[14,40,153,193,234,250,252,282,327,343,361],"unresectable":[15],"melanoma":[16,341],"that":[17,212,271],"failed":[18],"at":[19,79,162],"least":[20],"one":[21],"regimen":[22],"and":[23,53,57,64,89,120,125,156,179,195,204,255,262,284,290,309,316,320,349],"were":[24,86,116,280,358,367],"IPI":[25,31,69,76,137,337,357],"na\u00efve":[26],"(34),":[27],"or":[28,94,100,113,159,217,224],"progressed":[29],"after":[30],"(92).":[32],"We":[33],"assess":[34],"its":[35],"toxicity":[36,221],"especially":[37],"in":[38,68,225,229,336],"those":[39],"prior":[41,235],"dose":[42,103,245],"limiting":[43,104,246],"immune":[44],"related":[45],"adverse":[46],"events":[47],"(irAEs)":[48],"IPI,":[50],"update":[51],"survival":[52,174,183,334],"response":[54,144,158,168],"duration":[55,166],"data,":[56],"characterize":[58],"myeloid":[59],"derived":[60],"suppressor":[61,277],"cell":[62,66,296],"(MDSC)":[63,279],"T":[65,295],"subsets":[67],"refractory":[70,74,138,338],"pts.":[71],"Methods:":[72],"Pts":[73],"received":[77,121],"NIVO":[78,122,339],"3":[80,263],"mg/kg:":[81],"two":[82],"cohorts":[83],"of":[84,167,199,313,346,351,365],"pts":[85,109,139,211,233],"A*0201":[87],"positive":[88],"had":[90,110,150,242,310],"either":[91],"grade":[92,101,111],"2":[93,112,196,241],"less":[95,114],"IPI-related":[96],"irAE":[97,105,249],"(10":[98],"pts),":[99],"3-4":[102,238],"(21":[106],"pts);":[107],"61":[108],"irAE,":[115],"not":[117,191,359],"HLA":[118],"restricted":[119],"alone.":[123],"Pre-":[124],"12":[126],"week":[127],"post-treatment":[128],"peripheral":[129],"blood":[130],"analyzed.":[132],"Results:":[133],"Median":[134,172],"follow-up":[135],"for":[136],"18.7":[141],"months":[142],"(mos);the":[143],"ratewas":[145],"29%":[146],"by":[147,304],"mWHO;":[148],"44%":[149],"clinical":[151],"benefit":[152],"confirmed":[154],"partial":[155],"complete":[157],"stable":[160,223],"disease":[161],"24":[163],"weeks":[164],"(CR+PR+SD).Median":[165],"14.3":[170],"mos.":[171,353],"progression-free":[173],"(PFS)":[175],"5.4":[177,352],"mos,":[178],"estimated":[180],"median":[181,344],"overall":[182],"(OS)":[184],"20.1":[186,347],"mos":[187,348],"(95%":[188,201,206],"CI:":[189,202],"17.0,":[190],"reached)":[192],"1":[194],"year":[197],"OS":[198,286,345],"69.2%":[200],"57.9-78.0%)":[203],"39.1%":[205],"CI":[207],"26.0-52.0%).":[208],"Of":[209,231],"14":[210],"have":[213],"completed":[214],"all":[215,227,259],"therapy":[216],"stopped":[218],"due":[219],"while":[222],"response,":[226],"remain":[228],"remission.":[230],"21":[232],"IPI-induced":[236],"grades":[237],"irAEs,":[239],"only":[240],"subsequent":[244],"(and":[247],"different)":[248],"NIVO,":[251],"8":[253,260],"PR":[254,261],"5":[256],"SD":[257,264],"seen;":[258],"are":[265],"without":[266],"progression.":[267],"Biomarker":[268],"studies":[269],"showed":[270],"circulating":[272,370],"pre-treatment":[273],"HLA-DR":[274],"lo/CD14+/CD11b+":[275],"myeloid-derived":[276],"cells":[278],"associated":[281,326],"progression":[283],"worse":[285],"(p":[287,298],"=":[288,299],"0.0001":[289],"0.0009).":[291],"Pre-treatment,":[292],"MDSC":[293,324],"suppressed":[294],"reactivity":[297],"0.006)":[300],"which":[301],"overcome":[303],"blockade":[306],"ex":[307],"vivo,":[308],"high":[311],"levels":[312],"VISTA,":[314],"CD244":[315],"BTLA.":[317],"Low":[318],"PD-L1":[319],"Tim3":[321],"expression":[322],"on":[323,369],"response.":[328],"Conclusions:":[329],"This":[330],"is":[331],"the":[332],"first":[333],"assessment":[335],"treated":[340],"pts,":[342],"PFS":[350],"Prior":[354],"irAEs":[355],"replicated":[360],"NIVO.":[362],"Novel":[363],"biomarkers":[364],"outcome":[366],"found":[368],"MDSC.":[371],"Clinical":[372],"trial":[373],"information:":[374],"NCT01176461.":[375]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-07-22T00:00:00"}